Table 2 Results of the association between SNHG15 and clinicopathological outcomes
From: Long non-coding RNA SNHG15 in various cancers: a meta and bioinformatic analysis
| Â | Â | Â | Â | Â | Â | Heterogeneity | ||
|---|---|---|---|---|---|---|---|---|
outcome | studies(n) | OR | 95%CI | P value | Model | Chi2 | I2 | P Value |
age(< 60 vs ≥60) | 4 | 0.98 | 0.65–1.48 | 0.912 | Fixed | 1.84 | 0% | 0.607 |
gender (male vs female) | 9 | 0.95 | 0.73–1.25 | 0.728 | Fixed | 12.44 | 35.7% | 0.133 |
TNM stage (III-IV vs I-II) | 6 | 3.01 | 2.15–4.23 | 0.000 | Fixed | 2.76 | 0% | 0.737 |
lymph node metastasis (positive vs negative) | 8 | 3.20 | 2.30–4.45 | 0.000 | Fixed | 3.20 | 0% | 0.866 |
tumor size (large vs small) | 7 | 1.88 | 0.91–3.89 | 0.087 | Random | 27.76 | 78.4% | 0.000 |
overall survival | 11 | 1.95 | 1.53–2.49 | 0.000 | Fixed | 6.43 | 0% | 0.778 |
disease-free survival | 2 | 2.31 | 1.48–3.61 | 0.000 | Fixed | 0.05 | 0% | 0.822 |